Confluence Pharmaceuticals
2010
FOUNDED
PRIVATE
STATUS
1-10
EMPLOYEES
Angel
LATEST DEAL TYPE
$10K
LATEST DEAL AMOUNT
1
INVESTORS
Description
Developer of therapeutic medications intended for neurological development disorders. The company's medications focuses on therapeutic drug development, enabling patients to get medications to treat core social, communication and cognitive impairments associated with Fragile X Syndrome and Autism Spectrum Disorders.
Website
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Primary Office
- 4904 Deer Ridge Drive South
- Carmel, IN 46033
- United States
+1 (317) 000-0000
Request full access to PitchBook
You’re viewing a free company profile from the PitchBook Platform. To explore Confluence Pharmaceuticals’s full profile, request a free trial.
Confluence Pharmaceuticals Valuation and Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 2. Angel (individual) | 03-Oct-2018 | $10K | 00.000 | Completed | Generating Revenue | |
| 1. Later Stage VC (Series A2) | 07-Nov-2017 | 00.00 | 00.00 | Completed | Generating Revenue |
Confluence Pharmaceuticals Investors (1)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Board Seat |
Contact Info |
|---|---|---|---|---|---|---|
| Elevate Ventures | Venture Capital | Minority | 000 0000 | 000000 0 |
Confluence Pharmaceuticals Executive Team (5)
Confluence Pharmaceuticals Board Members (3)
| Name | Representing | Role | Since | Contact Info |
|---|---|---|---|---|
| Boyd Sturdevant Jr. | Confluence Pharmaceuticals | Co-Founder and Chairman | 000 0000 | |
| Phil Lodato JD | Elevate Ventures | Board Member | 000 0000 | |
| Steven Johns | Confluence Pharmaceuticals | Co-Founder, Chief Executive Officer, President & Board Member | 000 0000 |